Equities researchers at Oppenheimer initiated coverage on shares of Alpine Immune Sciences (NASDAQ:ALPN) in a report issued on Friday. The firm set an “outperform” rating and a $13.00 price target on the biotechnology company’s stock. Oppenheimer’s price target indicates a potential upside of 80.06% from the company’s previous close.
Other research analysts also recently issued reports about the company. Zacks Investment Research raised Alpine Immune Sciences from a “sell” rating to a “hold” rating in a research note on Friday, June 8th. ValuEngine raised Alpine Immune Sciences from a “strong sell” rating to a “sell” rating in a research note on Friday, June 1st. Citigroup began coverage on Alpine Immune Sciences in a research note on Thursday. They set an “outperform” rating and a $13.00 price target on the stock. Finally, Wedbush began coverage on Alpine Immune Sciences in a research note on Thursday, May 17th. They set an “outperform” rating and a $13.00 price target on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $13.60.
Shares of Alpine Immune Sciences opened at $7.22 on Friday, MarketBeat.com reports. The stock has a market capitalization of $105.23 million, a PE ratio of -6.02 and a beta of 0.59. The company has a debt-to-equity ratio of 0.05, a quick ratio of 26.71 and a current ratio of 26.70. Alpine Immune Sciences has a 1 year low of $6.85 and a 1 year high of $12.87.
Alpine Immune Sciences (NASDAQ:ALPN) last announced its quarterly earnings data on Monday, May 14th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.02. The business had revenue of $0.32 million during the quarter, compared to analyst estimates of $0.13 million. equities research analysts forecast that Alpine Immune Sciences will post -1.9 EPS for the current fiscal year.
Hedge funds have recently bought and sold shares of the stock. Wells Fargo & Company MN acquired a new position in Alpine Immune Sciences during the 4th quarter worth approximately $118,000. Millennium Management LLC acquired a new position in Alpine Immune Sciences during the 4th quarter worth approximately $205,000. Renaissance Technologies LLC raised its stake in Alpine Immune Sciences by 29.9% during the 4th quarter. Renaissance Technologies LLC now owns 67,500 shares of the biotechnology company’s stock worth $756,000 after buying an additional 15,521 shares during the period. Finally, Victory Capital Management Inc. raised its stake in Alpine Immune Sciences by 40.3% during the 1st quarter. Victory Capital Management Inc. now owns 72,302 shares of the biotechnology company’s stock worth $578,000 after buying an additional 20,751 shares during the period. 56.95% of the stock is currently owned by institutional investors and hedge funds.
Alpine Immune Sciences Company Profile
Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer.
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.